is a topic covered in the Johns Hopkins ABX Guide
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
- HIV-infected patients who are treatment-experienced and have at least one DRV resistance mutation, in combination with other antiretrovirals (DRV/r 600/100 mg twice daily).
- HIV-infected patients who are treatment-naive (DRV/r 800/100 mg once daily or DRV/c 800/150 mg once daily).
- HIV-infected children (>3 years)
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: January 12, 2016
TY - ELEC
T1 - Darunavir
ID - 540156
A1 - Hsu,Alice,Pharm.D.
AU - Pham,Paul,Pharm.D.
AU - Smith,Janessa,Pharm.D. BCPS
Y1 - 2016/01/12/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540156/all/Darunavir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine